Sightera is a techbio spin-off from the University of Antwerp and the University Hospital of Antwerp. Sightera’s drug discovery approach starts with capturing therapeutic effects from complex patient-derived models to accelerate the discovery of novel therapies beyond single-target strategies. Through an exclusive partnership with the University of Antwerp’s academic robotic screening platform, we generate large proprietary datasets to train our AI models for efficient identification and optimization of unique small molecules in cancer and regenerative medicine applications. Our prediction engine uses machine learning and deep learning to produce and prioritize compounds based on clinical relevance, patentability, and drug-like properties. Promising candidates are synthesized and experimentally validated in lab grown patient-derived models that accurately replicate disease biology. This enables patient stratification and speeds up lead optimization, delivering high-value, patient-relevant drug candidates with strong therapeutic potential.
Company Details
- Employees
- 2
- Address
- Galileilaan 15, Darwin Incubator,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- DrugVision.AI.
- HQ
- Antwerp, Flemish Region
Sightera Biosciences Questions
Sightera Biosciences's website is https://www.sightera-biosciences.com
Sightera Biosciences's LinkedIn profile is https://be.linkedin.com/company/sightera-biosciences
Sightera Biosciences has
2 employees.
View email and phone details for 2
employees at Sightera Biosciences.
Sightera Biosciences's industry is
Biotechnology Research
Sightera Biosciences's top competitors are
Drugvision.ai,
Labo Mérilo,
Mindoo Ai,
Orbits Oncology,
Epicure Vision,
Cavell,
Specifix,
Yun Probiotherapy,
Spotable,
Agomab.
Sightera Biosciences's categories are Biotechnology Research
